托法替布在难治性多器官受累结节病患者中的挽救性应用。 - Suppr

Suppr

超能文献

Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement.

作者信息

Farinha Inês, Ferreira Pedro Gonçalo

机构信息

Hospital and University Centre of Coimbra.

出版信息

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Jun 28;41(2):e2024019. doi: 10.36141/svdld.v41i2.15655.

DOI:10.36141/svdld.v41i2.15655

PMID:38940706

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11275545/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf8/11275545/8abfed0985fc/SVDLD-41-19-g001.jpg

相似文献

Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement.

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Jun 28;41(2):e2024019. doi: 10.36141/svdld.v41i2.15655.

Treatment of Multiorgan Sarcoidosis With Tofacitinib.

ACR Open Rheumatol. 2020 Feb;2(2):106-109. doi: 10.1002/acr2.11112. Epub 2020 Jan 9.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis.

Cureus. 2023 Sep 17;15(9):e45416. doi: 10.7759/cureus.45416. eCollection 2023 Sep.

Cutaneous sarcoidosis: Lupus pernio and more.

Ital J Dermatol Venerol. 2022 Jun;157(3):220-227. doi: 10.23736/S2784-8671.21.07027-4. Epub 2022 Mar 11.

Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.

J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. doi: 10.1097/MPG.0000000000003616. Epub 2022 Sep 19.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

Cardiac Involvement In Multiorgan Sarcoidosis: Prognostic and Therapeutic Implications.

Cureus. 2020 Sep 29;12(9):e10714. doi: 10.7759/cureus.10714.

Multiorgan Involvement of Chemotherapy-Induced Sarcoidosis Mimicking Progression of Lymphoma on FDG PET/CT.

Clin Nucl Med. 2017 Sep;42(9):702-703. doi: 10.1097/RLU.0000000000001735.

Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.

Arthritis Rheum. 2003 Dec;48(12):3542-3. doi: 10.1002/art.11357.

引用本文的文献

Sarcoidosis: molecular mechanisms and therapeutic strategies.

Mol Biomed. 2025 Feb 5;6(1):6. doi: 10.1186/s43556-025-00244-z.

Autoantibodies in sarcoidosis: Innocent bystander or promising biomarker for organ involvement?

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024056. doi: 10.36141/svdld.v41i4.16043.

本文引用的文献

Generic Tofacitinib-A More Affordable JAK Inhibitor.

Mayo Clin Proc. 2024 Jan;99(1):4-6. doi: 10.1016/j.mayocp.2023.11.014.

Prognosis of sarcoidosis and factors affecting prognosis.

Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023054. doi: 10.36141/svdld.v40i4.13244.

Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review.

Cureus. 2023 Sep 8;15(9):e44901. doi: 10.7759/cureus.44901. eCollection 2023 Sep.

Tofacitinib for sarcoidosis, a new potential treatment.

Int J Rheum Dis. 2022 Nov;25(11):1217-1219. doi: 10.1111/1756-185X.14441.

Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma.

Clin Exp Dermatol. 2022 Oct;47(10):1868-1870. doi: 10.1111/ced.15290. Epub 2022 Aug 5.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.

Lung. 2021 Apr;199(2):147-153. doi: 10.1007/s00408-021-00436-8. Epub 2021 Apr 7.

Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series.

J Am Acad Dermatol. 2021 Feb;84(2):581-583. doi: 10.1016/j.jaad.2020.10.016. Epub 2020 Oct 16.

Treatment of Multiorgan Sarcoidosis With Tofacitinib.

ACR Open Rheumatol. 2020 Feb;2(2):106-109. doi: 10.1002/acr2.11112. Epub 2020 Jan 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement.

作者信息

Farinha Inês, Ferreira Pedro Gonçalo

机构信息

Hospital and University Centre of Coimbra.

出版信息

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Jun 28;41(2):e2024019. doi: 10.36141/svdld.v41i2.15655.

DOI:10.36141/svdld.v41i2.15655

PMID:38940706

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11275545/

Abstract

摘要

相似文献

Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement.

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Jun 28;41(2):e2024019. doi: 10.36141/svdld.v41i2.15655.

Treatment of Multiorgan Sarcoidosis With Tofacitinib.

ACR Open Rheumatol. 2020 Feb;2(2):106-109. doi: 10.1002/acr2.11112. Epub 2020 Jan 9.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis.

Cureus. 2023 Sep 17;15(9):e45416. doi: 10.7759/cureus.45416. eCollection 2023 Sep.

Cutaneous sarcoidosis: Lupus pernio and more.

Ital J Dermatol Venerol. 2022 Jun;157(3):220-227. doi: 10.23736/S2784-8671.21.07027-4. Epub 2022 Mar 11.

Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.

J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. doi: 10.1097/MPG.0000000000003616. Epub 2022 Sep 19.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

Cardiac Involvement In Multiorgan Sarcoidosis: Prognostic and Therapeutic Implications.

Cureus. 2020 Sep 29;12(9):e10714. doi: 10.7759/cureus.10714.

Multiorgan Involvement of Chemotherapy-Induced Sarcoidosis Mimicking Progression of Lymphoma on FDG PET/CT.

Clin Nucl Med. 2017 Sep;42(9):702-703. doi: 10.1097/RLU.0000000000001735.

Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.

Arthritis Rheum. 2003 Dec;48(12):3542-3. doi: 10.1002/art.11357.

引用本文的文献

Sarcoidosis: molecular mechanisms and therapeutic strategies.

Mol Biomed. 2025 Feb 5;6(1):6. doi: 10.1186/s43556-025-00244-z.

Autoantibodies in sarcoidosis: Innocent bystander or promising biomarker for organ involvement?

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024056. doi: 10.36141/svdld.v41i4.16043.

本文引用的文献

Generic Tofacitinib-A More Affordable JAK Inhibitor.

Mayo Clin Proc. 2024 Jan;99(1):4-6. doi: 10.1016/j.mayocp.2023.11.014.

Prognosis of sarcoidosis and factors affecting prognosis.

Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023054. doi: 10.36141/svdld.v40i4.13244.

Cureus. 2023 Sep 8;15(9):e44901. doi: 10.7759/cureus.44901. eCollection 2023 Sep.

Tofacitinib for sarcoidosis, a new potential treatment.

Int J Rheum Dis. 2022 Nov;25(11):1217-1219. doi: 10.1111/1756-185X.14441.

Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma.

Clin Exp Dermatol. 2022 Oct;47(10):1868-1870. doi: 10.1111/ced.15290. Epub 2022 Aug 5.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.

Lung. 2021 Apr;199(2):147-153. doi: 10.1007/s00408-021-00436-8. Epub 2021 Apr 7.

Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series.

J Am Acad Dermatol. 2021 Feb;84(2):581-583. doi: 10.1016/j.jaad.2020.10.016. Epub 2020 Oct 16.

Treatment of Multiorgan Sarcoidosis With Tofacitinib.

ACR Open Rheumatol. 2020 Feb;2(2):106-109. doi: 10.1002/acr2.11112. Epub 2020 Jan 9.